AbCellera Biologics (ABCL) Projected to Post Earnings on Thursday

AbCellera Biologics (NASDAQ:ABCL) is expected to be announcing its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $7.58 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

AbCellera Biologics Trading Down 1.3 %

Shares of NASDAQ ABCL opened at $2.99 on Tuesday. The firm’s 50 day moving average price is $3.09 and its 200-day moving average price is $2.84. AbCellera Biologics has a 52-week low of $2.34 and a 52-week high of $5.26.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ABCL shares. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 target price (down previously from $14.00) on shares of AbCellera Biologics in a research note on Tuesday, November 5th. Benchmark restated a “hold” rating on shares of AbCellera Biologics in a research report on Tuesday, November 5th. Finally, KeyCorp lowered their price objective on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.